| research round-up
by multiple organ failure and the development of sepsis with perimammary abscesses. extended liposuction of the abdomen and thighs, bilateral augmentation mammaplasty, and stripping of both greater saphenous veins were combined.
INTERNATIONALWEB SURVEY SHOWS HIGH PREVALENCE OF SYMPTOMATIC TESTOSTERONE DEFICIENCY INMEN
Trinick TR, Feneley MR, Welford H, Carruthers M. Aging Male. 2011 March; 14(1): 10–5
increasingly apparent, its prevalence in the general population remains unrecognised. A large web-based survey was undertaken over 3 years to study the scale of this missed diagnosis. Methods: An online questionnaire giving the symptoms characterising testosterone deficiency syndrome (Aging Male symptoms — AMs — scale) was set up on three web sites, together with questions about possible contributory factors. Result:. of over 10 000 men, mainly from the uK and usA, who responded, 80% had moderate or severe scores likely to benefit from testosterone replacement therapy (trt). the average age was 52, but with many in their 40s when the diagnosis of ‘late onset hypogonadism’ is not generally considered. other possible contributory factors to the high testosterone deficiency scores reported were obesity (29%), alcohol (17.3%), testicular problems such as mumps orchitis (11.4%), prostate problems (5.6%), urinary infection (5.2%) and diabetes 5.7%. Conclusions: in this self-selected large international sample of men, there was a very
t
hough the CLiniCAL signiFiCAnCe of testosterone deficiency is becoming
high prevalence of scores which if clinically relevant would warrant a therapeutic trial of testosterone treatment. this study suggests that there are large numbers of men in the community whose testosterone deficiency is neither being diagnosed nor treated.
TREATMENT OF SEVERE DROOLINGWITH BOTULINUM TOXIN IN AMYOTROPHIC LATERAL SCLEROSIS AND PARKINSON’S DISEASE: EFFICACY AND POSSIBLE MECHANISMS
Møller E, Karlsborg M, Bardow A, Lykkeaa J, Nissen FH, Bakke M. Acta Odontol Scand. 2011 May; 69(3): 151–7
impediment. previous treatments of drooling have little effect or are effective but with severe side effects. therefore, there is a need to test new methods such as the use of botulinum toxin type A (btX-A). Material and methods: this open, prospective study deals with treatment of drooling in 12 patients with amyotrophic lateral sclerosis and three with parkinson’s disease. injections of btX-A (botox) were given into the parotid (25–40 units) and submandibular (15–30 units) glands with ultrasonographic guidance. After btX-A treatment, the patients were followed for 2 months with evaluations every second week by means of self-assessed rating scales for drooling intensity, discomfort and treatment effect, and determination of unstimulated whole saliva (uWs) flow rate, and inorganic and organic uWs composition. the treatment was repeated up to four times,
d
rooLing in neurodegenerAtive diseases is associated with social
but seven patients dropped out shortly after the first treatment due to marked worsening of their disease-related condition. Results: drooling and flow were reduced (P < 0.05) 2 weeks after treatment, without side-effects. the maximal reductions during the observation period were 40% for drooling and 30% for flow. there was a systematic variation in flow during the observation period, with an initial decrease and then an increase followed by a second decrease. Amylase activity and total protein concentration generally increased with decreasing flow (P≤ 0.03). Conclusion: inhibition of acetylcholine release from postganglionic parasympathetic nerve endings by injection of btX-A into salivary glands seemed useful for secondary sialorrhoea, although cyclic variations in flow may occur, possibly due to transitory sprouting and regeneration.
prime-journal.com | May 2011
❚
67
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84